COFCO Biotechnology (000930) Fundamentals 2026 — Revenue Analysis | SniperIQ
COFCO Biotechnology (000930) is a CN-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ¥8.5B, trading at ¥4.57 on the SHZ. This SniperIQ fundamentals page covers COFCO Biotechnology's valuation, profitability (net margin -0.7%), revenue (¥17.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is COFCO Biotechnology's market cap?
COFCO Biotechnology (000930) has a market capitalization of approximately ¥8.5B, trading at ¥4.57 on the SHZ. Market cap moves with the live share price.
What is COFCO Biotechnology's P/E ratio?
COFCO Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is COFCO Biotechnology?
COFCO Biotechnology runs a net profit margin of -0.7%, a gross margin of 7.8%, and an operating margin of -1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does COFCO Biotechnology generate?
COFCO Biotechnology reported revenue of ¥17.5B for fiscal year 2025, with net income of ¥38M and earnings per share (EPS) of 0.0207. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does COFCO Biotechnology pay a dividend?
COFCO Biotechnology offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is COFCO Biotechnology financially healthy?
COFCO Biotechnology carries a debt-to-equity ratio of 0.31x and a current ratio of 1.17x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is COFCO Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For COFCO Biotechnology (000930) the key facts are: market cap ¥8.5B, revenue ¥17.5B, 52-week range 4.24-8.14. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track COFCO Biotechnology's full fundamentals live
Get COFCO Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.